Background Medication-related osteonecrosis of the jaw (MRONJ), which was first reported
as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in bisphosphonate users, is a …

Background Medication‐related osteonecrosis of the jaw (MRONJ) is a severe adverse
reaction experienced by some individuals to certain medicines commonly used in the …

PURPOSE The aim of this work is to provide evidence-based guidance on the management
of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Medication‐related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of
antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition …

Abstract Purpose of Review Osteonecrosis of the jaw (ONJ) is a rare and severe necrotic
bone disease reflecting a compromise in the body's osseous healing mechanisms and …

Skeletal-related events (SREs) are complications of bone metastases and carry a significant
patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand …

The link between medication-related osteonecrosis of the jaw (MRONJ) and bone
modulating drugs, such as bisphosphonates and denosumab, is well established, and the …

Objectives. To review the available literature on medication‐related osteonecrosis of the jaw
(MRONJ) associated with antiangiogenics in antiresorptive‐naïve individuals. Methods. A …

Study Objective Acute kidney injury (AKI) is a common condition associated with both short‐
term and long‐term consequences including dialysis, chronic kidney disease, and mortality …